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Renin–angiotensin–aldosterone system (RAAS) inhibition
has become the cornerstone of evidence-based therapies in
cardiovascular disease, including patients with hypertension,
high cardiovascular risk, left ventricular dysfunction after
myocardial infarction, and heart failure with reduced ejection
fraction (1–3). Both angiotensin-converting enzyme inhib-
itors (ACEIs) and angiotensin II receptor blockers (ARBs)
have been shown to improve morbidity and mortality in
these populations, although evidence is more consistent withSee page 650ACEI and single RAAS inhibition. However, for patients
with chronic kidney disease (CKD), scarce data are availa-
ble on the clinical outcome beneﬁt with these therapies,
especially in patients without diabetes. As such, a recent
Cochrane review deemed the current evidence uncertain
for the effectiveness of ACEIs or ARBs in patients with
stage 1 to 3 CKD without diabetes (4).
The data presented by Molnar et al. (5) in this issue of the
Journal are therefore of timely fashion. In this manuscript,
the authors have retrospectively investigated the effect of
de novo prescription of ACEI or ARB therapy in patients
with nondialysis CKD on mortality in a large population.*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
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employer/institution University of Groningen.Data on no less than 659,546 patients with CKD were
available at the start, with the primary analysis being carried
out on 141,413 patients, in whom ACEI or ARB therapy
was started in 18% within 1 year. Of note, this was not
a randomized controlled trial, and the authors therefore
had to use rigorous and elaborate statistical analysis to
account for the inherent reasons that patients would be
prescribed the treatment of interest. Propensity scoring,
marginal structural modeling, and inverse probability of
treatment and censoring weights were used. All of these
statistical techniques were required to balance the treatment
groups, which were clearly different at baseline. As expected,
patients who were administered RAAS inhibitors were
those who were supposed to be prescribed these therapies
as indicated in guidelines: more frequent diabetes, higher
blood pressure and hypertension, cardiovascular disease, and
heart failure. When accounting for all these possible con-
founders, de novo ACEI/ARB treatment was associated
with a signiﬁcant reduction in death rates in both intention-
to-treat analysis (hazard ratio: 0.81; 95% conﬁdence interval:
0.78 to 0.84) and as-treated analysis (odds ratio: 0.37; 95%
conﬁdence interval: 0.34 to 0.41). This effect was consistent
among subgroups, although nondiabetic persons tended to
show less beneﬁt. One could argue that the observed effect
is even an underestimation of the true effect because the
treated population clearly had a higher prevalence of car-
diovascular disease, which in general should be associated
with increased mortality. On the other hand, these patients
may have been monitored more closely, with more intensive
treatment other than RAAS inhibition, and therefore may
have received better or at least more thorough medical
attention, which could in part explain the results. Further-
more, there are some other important limitations to the
analysis. First, although rigorous statistical methods are
used, this can never totally exclude the existence of residual
confounding. Second, the authors needed to exclude a large
number of patients who had been exposed to RAAS
inhibitors before and more than 50,000 patients who had
no information on ACEI/ARB treatment, the latter com-
prising more than twice the number of patients who began
therapy in the ﬁrst year. The effects of these selection
processes on the eventual outcome are unclear. Finally, the
authors make no distinction between ACEI and ARB
treatment, whereas mortality beneﬁt in other populations
is greater or similar for ACEI versus ARB therapy (3,6).
The recently updated Kidney Disease Improving Global
Outcomes clinical practice guideline on CKD and blood
pressure recommends treatment with ACEI and ARB as
ﬁrst-line therapy in patients with concomitant hypertension
and microalbuminuria or macroalbuminuria to slow the
progression of CKD (7). Because most (if not all) patients
with CKD have hypertension (or blood pressures greater
than the target range of 130/80 mm Hg), these therapies
are indicated in the majority of patients. The guidelines
make no distinction between diabetic and nondiabetic
CKD. Evidence that supports the data in nondiabetic
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660patients comes from the REIN (Ramipril Efﬁcacy In
Nephropathy) trials (8). In diabetic patients, the IDNT
(Irbesartan Diabetic Nephropathy Trial) and RENAAL
(Reduction of Endpoints in NIDDM with the Angiotensin
II Antagonist Losartan) trials demonstrated that irbesartan
and losartan slowed the progression of CKD (9,10).
However, in both RENAAL and IDNT, there was no
reduction in all-cause mortality, although neither was
powered to answer this speciﬁc question. The current
manuscript therefore differs signiﬁcantly from these two
randomized trials in that the observed treatment beneﬁt was
most pronounced in patients with diabetes. Of course, the
power of the current study was signiﬁcantly greater com-
pared with IDNT and RENAAL together, but the latter
were randomized controlled trials, and given the discrepancy
between the ﬁndings, caution should be taken in the inter-
pretation of the current data.
It is important to highlight again that the patients actually
treated with ACEI/ARB were those who had concomitant
cardiovascular disease, and should therefore have been
considered for treatment with RAAS inhibitors on the basis
of that speciﬁc condition as well. Because CKD is often
prevalent in diseases such as coronary artery disease,
hypertension, and heart failure, and RAAS inhibitor therapy
has been associated with improved cardiovascular outcomes
in these populations, it is also less surprising that mortality
beneﬁt particularly was observed in these subgroups.
Last, it can be questioned whether mortality alone is
the best outcome measure in patients with CKD. Although
it is the most deﬁnite and therefore least-biased endpoint,
other important outcomes, such as time spent off dialysis,
incidence of heart failure, and quality of life, also should
be considered. Approximately 2 of 3 patients with CKD
actually die before they reach dialysis. A therapy that
prolongs life will thus have a major impact in this population
(11,12). However, any therapy in CKD that prolongs
survival potentially increases the likelihood of dialysis
because patients live longer and thus have a higher chance to
progress to end-stage renal disease, which obviously affects
quality of life. Thus, studies that evaluate the effect of
interventions in CKD should analyze death (or more
speciﬁcally, cardiovascular death) and end-stage renal disease
together as competing events.
Overall, there is a need for more convincing mortality
and outcome data in patients with CKD, not only in those
with primary renal disease but also in those with conditions
for which CKD is prevalent, such as hypertension, heart
failure, and post-myocardial infarction. Although the pre-
sent study does not give deﬁnite answers and the study
design has inherent limitations, it may give a glimpse into
the possible mortality beneﬁt of ACEI/ARBs in CKD.The obvious (and right) question now is whether to conduct
a properly powered phase 3 mortality trial. The most likely
(and wrong) answer is that the costs, time, and generic
nature of the drugs will prohibit this. It is up to the
cardiovascular and nephrology research community to defy
these odds.
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